Dopamine receptor antagonists - Pipeline Insight, 2022
This report can be delivered to the clients within 2-3 working days
DelveInsight’s, “Dopamine receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Dopamine receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Dopamine receptor antagonists: Overview
Dopamine exerts its effect via a family of cell surface G protein–coupled receptors (GPCRs), classified as D1-like (ie, D1 and D5) and D2-like (ie, D2, D3 and D4). Among these receptors, D1, D3 and D4 receptors interact with the renin-angiotensin-aldosterone system (RAAS), whereas the D2 and D5 receptors interact with the sympathetic nervous system. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as Antiemetics, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with Neuroleptic Malignant Syndrome.
'Dopamine receptor antagonists - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dopamine receptor antagonists pipeline landscape is provided which includes the disease overview and Dopamine receptor antagonists treatment guidelines. The assessment part of the report embraces, in depth Dopamine receptor antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dopamine receptor antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Dopamine receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dopamine receptor antagonists Emerging Drugs
Further product details are provided in the report……..
Dopamine receptor antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Dopamine receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:
Dopamine receptor antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dopamine receptor antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dopamine receptor antagonists drugs.
Dopamine receptor antagonists Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Dopamine receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Dopamine receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Dopamine receptor antagonists: Overview
Dopamine exerts its effect via a family of cell surface G protein–coupled receptors (GPCRs), classified as D1-like (ie, D1 and D5) and D2-like (ie, D2, D3 and D4). Among these receptors, D1, D3 and D4 receptors interact with the renin-angiotensin-aldosterone system (RAAS), whereas the D2 and D5 receptors interact with the sympathetic nervous system. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as Antiemetics, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with Neuroleptic Malignant Syndrome.
'Dopamine receptor antagonists - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dopamine receptor antagonists pipeline landscape is provided which includes the disease overview and Dopamine receptor antagonists treatment guidelines. The assessment part of the report embraces, in depth Dopamine receptor antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dopamine receptor antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Dopamine receptor antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Dopamine receptor antagonists.
This segment of the Dopamine receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dopamine receptor antagonists Emerging Drugs
- Iloperidone: Vanda Pharmaceuticals
- NG101: Neurogastrx
Further product details are provided in the report……..
Dopamine receptor antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Dopamine receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Dopamine receptor antagonists
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Dopamine receptor antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dopamine receptor antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dopamine receptor antagonists drugs.
Dopamine receptor antagonists Report Insights
- Dopamine receptor antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Dopamine receptor antagonists drugs?
- How many Dopamine receptor antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dopamine receptor antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dopamine receptor antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Dopamine receptor antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Emalex Biosciences
- Impel NeuroPharma
- Intra-Cellular Therapies
- Vanda Pharmaceuticals
- Neurogastrx
- Ecopipam
- INP 105
- ITI-333
- Iloperidone
- NG101
Introduction
Executive Summary
Dopamine receptor antagonists: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Iloperidone: Vanda Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
INP 105: Impel NeuroPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
Comparative Analysis
ITI-333: Intra-Cellular Therapies
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Dopamine receptor antagonists Key Companies
Dopamine receptor antagonists Key Products
Dopamine receptor antagonists- Unmet Needs
Dopamine receptor antagonists- Market Drivers and Barriers
Appendix
Executive Summary
Dopamine receptor antagonists: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Iloperidone: Vanda Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
INP 105: Impel NeuroPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
Comparative Analysis
ITI-333: Intra-Cellular Therapies
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Dopamine receptor antagonists Key Companies
Dopamine receptor antagonists Key Products
Dopamine receptor antagonists- Unmet Needs
Dopamine receptor antagonists- Market Drivers and Barriers
Appendix
